David Olagnier

Associate Professor (with tenure)

Aarhus University

Denmark

Research Interests

Explore related searches

Professors in Immunology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

David Olagnier is an Associate Professor (with tenure) at Aarhus University in Denmark. His research primarily focuses on oncolytic virotherapy, drug discovery targeting protein-protein interactions, and the immune response to viral infections. His recent publications include work on the dual roles of itaconate, as well as the therapeutic potential of animal viruses in treating human cancers.

Articles (25)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (27)

Mogens Johannsen

Aarhus University

DENMARK

David Olagnier

Research Interests

Explore related searches

Contact this professor

About

Articles (25)

Oncolytic virotherapy

Fragment-Based Drug Discovery of Novel High-affinity, Selective, and Anti-inflammatory Inhibitors of the Keap1-Nrf2 Protein-Protein Interaction

Oncolytic viruses in action

Virus oncolytiques en action

Dual faces of itaconate and its derivatives

SAM68 directs STING signaling to apoptosis in macrophages

Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways

Breaking Barriers: Animal viruses as oncolytic and immunotherapeutic agents for human cancers

Editorial: Host-cell pathways modulated by influenza virus infection: new insight into pathogenetic mechanisms and cell-targeted antiviral strategies.

The HIF transcription network exerts innate antiviral activity in neurons and limits brain inflammation.

Author Correction

Early host defense against virus infections

HSP60 controls mitochondrial ATP generation for optimal virus-specific IL-21-producing CD4 and cytotoxic CD8 memory T cell responses

Response to the letter to editor "Clarification on Rigvir's mechanism: Interpretation of CD55 inhibition in oncolytic therapy".

Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1

Harnessing Autophagy to Overcome Antigen-Specific T-Cell Dysfunction: Implication for People Living with HIV-1

Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral development.

NRF2 activators inhibit influenza A virus replication by interfering with nucleo-cytoplasmic export of viral RNPs in an NRF2-independent manner.

Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug Discovery

Alternative pathways driven by STING

The lncRNA LUCAT1 is elevated in inflammatory disease and restrains inflammation by regulating the splicing and stability of NR4A2.

VPS34-dependent control of apical membrane function of proximal tubule cells and nutrient recovery by the kidney.

Regulation of innate immunity by Nrf2.

Inhibition of Glycolysis Impairs Retinoic Acid-Inducible Gene I-Mediated Antiviral Responses in Primary Human Dendritic Cells.

Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen.

Collaborators (27)

Mogens Johannsen

Robin Parks

Francesca Cutruzzola'

Jacob Giehm Mikkelsen

Vivien Schack

Seyed Mehdi Jafarnejad

Fatih Demir

Mark Denham

Line Reinert

Rasmus Bak

Wen-Hsien Hou

Manutea Christophe Serrero

Wibke Bechtel-Walz

Morten Kelder Skouboe

Mikkel Haarslev Schröder Marqvorsen

Jean-Pierre Routy

Laureano de la Vega

Joanna Kalucka

Dilip Narayanan

Michael Gajhede

Bao-cun Zhang

Anders Bach

Trine Hyrup Mogensen

Qi Wu

Attila Ozsvár

Esben B. Svenningsen

Sara Marie Solbak

Make your next move.